Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Tylenol Sales Could Shrink By Half With Acetaminophen Dose Restriction

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson could lose roughly $500 million in nonprescription Tylenol sales if FDA follows an advisory committee recommendation to switch 500-g tablets of acetaminophen to Rx status

You may also be interested in...



McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol

McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.

McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol

McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.

McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol

McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS103136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel